文章(zhang)來(lai)源：華潤(run)（集團）有(you)限公司(si) 發布(bu)時間：2009-08-26
華潤(run)集團旗下三九醫藥股份有限公(gong)司發布2008年(nian)半年(nian)度報告，公(gong)司實(shi)現(xian)營(ying)業收入19.10億(yi)元，同(tong)比(bi)(bi)增(zeng)長(chang)19.94％；營(ying)業利潤(run)2.77億(yi)元，同(tong)比(bi)(bi)增(zeng)長(chang)116.55％；歸屬(shu)于(yu)母公(gong)司的(de)(de)凈利潤(run)為2.09億(yi)元，同(tong)比(bi)(bi)增(zeng)長(chang)122.95％；實(shi)現(xian)每股收益0.21元。公(gong)告還(huan)稱，經財務部門初步(bu)測算，預計今年(nian)前九個月，實(shi)現(xian)的(de)(de)歸屬(shu)于(yu)母公(gong)司所有者的(de)(de)凈利潤(run)與(yu)上年(nian)同(tong)期相比(bi)(bi)增(zeng)長(chang)100%-150%。
今年上半年，三(san)九(jiu)醫(yi)藥(yao)股份公司醫(yi)藥(yao)工業收(shou)入同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)23.72%，其(qi)中(zhong)OTC銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)額(e)同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)14%，中(zhong)藥(yao)處方(fang)藥(yao)銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)額(e)同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)50%，抗生素(su)及(ji)原料(liao)藥(yao)銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)額(e)同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)66%，延續了較(jiao)快(kuai)的(de)增(zeng)(zeng)長(chang)(chang)勢頭(tou)，免煎中(zhong)藥(yao)銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)額(e)同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)55%。產品(pin)(pin)方(fang)面，主(zhu)打產品(pin)(pin)感冒靈(ling)銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)26%，達(da)到2.65億元(yuan)；皮炎(yan)(yan)平(ping)軟膏銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)達(da)到2.46億元(yuan)，同(tong)(tong)(tong)比(bi)增(zeng)(zeng)長(chang)(chang)12.60%，參附及(ji)生脈銷(xiao)(xiao)(xiao)售(shou)(shou)(shou)分(fen)別增(zeng)(zeng)長(chang)(chang)52%及(ji)230%，三(san)九(jiu)皮炎(yan)(yan)平(ping)、三(san)九(jiu)胃泰保持平(ping)穩；新產品(pin)(pin)小(xiao)兒感冒靈(ling)、復方(fang)氨酚(fen)烷胺、無水頭(tou)孢唑林(lin)鈉等增(zeng)(zeng)長(chang)(chang)快(kuai)速(su)。